improving 30-day hf readmission rates with biomarker-guided therapy

26
Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Upload: kesler

Post on 19-Feb-2016

56 views

Category:

Documents


2 download

DESCRIPTION

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy. Heart Failure Epidemiology (US Data). CHF Hospitalizations by Age, 2000 and 2010. Consequences of Heart Failure. Impact of Affordable Care Act on HF Readmission. Impact of Affordable Care Act on HF Readmission (cont). - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Page 2: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy
Page 3: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Heart Failure Epidemiology (US Data)

Page 4: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

CHF Hospitalizations by Age, 2000 and 2010

Page 5: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Consequences of Heart Failure

Page 6: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Impact of Affordable Care Act on HF Readmission

Page 7: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Impact of Affordable Care Act on HF Readmission (cont)

Page 8: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

EVEREST Study

Page 9: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

EVEREST: NPs and Congestion Scores

Page 10: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Relationships Between Discharge BNP and Outcomes

Page 11: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Therapies With Effects on BNP Levels

Page 12: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

DOSE-AHF Study

Page 13: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Telemonitoring and Home-based Care

Page 14: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

The Importance of Serial NP Measurements for Prognostication

in Chronic HF

Page 15: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

PROTECT Study Primary End Point: Total Cardiovascular Events

Page 16: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

PROTECT Secondary End Points: HF Hospitalization and Rehospitalization

Page 17: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Guided Therapy Combined Analyses

Suggest Benefit, All-Cause Mortality

Page 18: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

The GUIDE-IT Trial

Page 19: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Home Testing

Page 20: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Abbreviations

Page 21: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Abbreviations (cont)

Page 22: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Abbreviations (cont)

Page 23: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

References

Page 24: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

References (cont)

Page 25: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

References (cont)

Page 26: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

References (cont)